Other languages Cantargia AB

Equities

CANTA

SE0006371126

Real-time Estimate Cboe Europe Other stock markets 16:25:00 27/06/2024 BST			5-day change	1st Jan Change
4.611 ^SEK	-1.22%		+2.35%	+23.43%

06-20	Cantargia AB Presents Phase 2 Clinical Data in Pancreatic Cancer with Nadunolimab At ESMO Gastrointestinal Cancer Congress 2024	CI
06-14	Cantargia AB Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cantargia AB Presents Phase 2 Clinical Data in Pancreatic Cancer with Nadunolimab At ESMO Gastrointestinal Cancer Congress 2024	06-20
Cantargia AB Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10	06-14
Cantargia Appoints New Chief Business Officer	06-11
Cantargia AB Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024	06-11
Cantargia Asco Presentation Highlights Positive Clinical Data on Nadunolimab Counteracting Neuropathy	06-01
Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy	05-23
Cantargia AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-21
Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	04-17
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	04-10
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer	04-08
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis	04-02
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia	03-27
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis	03-14
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer	03-05
Cantargia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22
Cantargia Secures US Approval to Start Patient Recruitment for Pancreatic Cancer Therapy	02-20
Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab	02-20
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy	02-12
Cantargia Reports Phase I Clinical Progress in the CAN10 Project	01-09
Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10	11-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cantargia AB

Equities

CANTA

SE0006371126

Other languages

Filters